News

The DESSOLVE I study is a prospective, open-label, non-randomized, single-arm study that is expected to enroll 30 patients at five clinical sites in Belgium, Australia and New Zealand.

GSK said that successful implementation of the Patent Box will secure new investment in the manufacture of the company’s next generation high-technology respiratory inhalation device for asthma and

Following this purchase, GSK will own 15,151,499 shares of Theravance common stock and Class A common stock, which represent approximately 19% of the total outstanding capital stock of

China Pediatric Pharma claims that a significant portion of the increase in sales is derived from an increase in sales for the ‘Cooer’ Series by $2.6m or 80%

Immunovaccine claims that its DepoVax platform is a lipid depot-based vaccine delivery and enhancement technology. Immunovaccine is currently testing the safety and tolerability of DepoVax in a Phase

Eisai said that SEP-190 is a non-benzodiazepine type GABAA agonist (non-benzodiazepine sedative hypnotic) that is effective in treating transient and chronic insomnia and that can be used over

In the initial rollout, 2,000 clinicians and staff use fingerprint biometrics to establish their identity in Genesis’s Epic software to order, verify or administer medications. In the next

APP Pharma claims that Topotecan for injection is therapeutically equivalent to the reference-listed drug Hycamtin, which is currently marketed by the GlaxoSmithKline. Topotecanfor injection is indicated for small

Medivation and Astellas Pharma said that the trial is evaluating 160mg/day of MDV3100 versus placebo. Conducted at sites in the US, Canada, Europe, Australia, South America and South